MedPath

Effect on Post-operative Pain of Tranexamic Acid Injection During Shoulder Surgery

Phase 3
Recruiting
Conditions
Shoulder Disease
Interventions
Registration Number
NCT05302986
Lead Sponsor
Elsan
Brief Summary

Arthroscopic shoulder surgery is a commonly performed minimally invasive surgery in which a camera (an arthroscope) is inserted inside the shoulder joint.

This surgery is responsible for moderate to severe pain. It may require the use of opioid analgesics in the acute phase. One of the components of this pain may be the postoperative hematoma.

Pain is one of the main causes of patient satisfaction failure after shoulder surgery. Finding ways to reduce this pain is a primary principle in the management of this surgery. Until now, this management requires the frequent use of morphine. However, this use of morphine may conduct to adverse effects (nausea/vomiting, constipation, malaise, sweating), and even public health problems such as addiction.

It is therefore interesting to look for ways to increase the patient's analgesia by other means, which will thus increase patient satisfaction and make his management more fluid. The effect on pain of hematoma reduction is rarely described in the scientific literature.

The hypothesis of this study is that the intraoperative administration of intravenous (IV) tranexamic acid can reduce the hematoma and thus decrease postoperative pain.The aim of this study is to demonstrate that the use of IV tranexamic acid intraoperatively, compared to a placebo (sodium chloride 0.9%), reduces postoperative pain after arthroscopic shoulder surgery.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
220
Inclusion Criteria

1 - Male or female aged 18 years old or more; 2- Patient requiring shoulder arthroscopy; 3 - Patient affiliated to a social security scheme; 4 - Patient informed on the study and who has signed the informed consent form.

Exclusion Criteria
    • Tranexamic acid contraindications (Hypersensitivity to the active substance or to any of the excipients, Acute venous or arterial thrombosis, Severe renal impairment, History of convulsions);
    • Pregnant or breastfeeding patient;
    • Patient under legal protection;
    • Patient taking part simultaneously to another clinical trial.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Surgery with intravenous injection of tranexamic acidTranexamic acid injectionThe dose will be 0.1 mg / kg (= 10 mg/kg) and diluted in a 100 mL infusion bag of sodium chloride. The product will have to be administered as a slow infusion over 10 minutes.
Surgery with intravenous injection of Placebo (0.9% sodium chloride)PlaceboA 100 mL infusion bag of sodium chloride will be administered as a slow infusion over 10 minutes.
Primary Outcome Measures
NameTimeMethod
Evaluation of the use of morphine treatments in the 24 postoperative hours (yes/no).At 24 hours post-operative

Evaluation of the use of morphine treatments in the 24 postoperative hours (yes/no).

Secondary Outcome Measures
NameTimeMethod
Evaluation of postoperative shoulder pain between the two groupsAt 24 hours and 7 days after surgery

Shoulder pain is assessed through a Visual Analog Scale (0-100) performed 24 hours post-operative and 7 days after surgery (online assessment with the help of software)

Evaluation of patient satisfaction between the two groupsThe day after surgery

Satisfaction will be assessed through an Evaluation of the Experience of General Anesthesia questionnaire.

Assessment of shoulder functionality between the two groupsBefore surgery and at the day 30 after surgery

The functionality of the shoulder will be evaluated by the Constant Score.

Evaluation of the safety of the treatments under study between the two groupsContinuously from surgery up to 30 days after surgery

Collection of adverse events throughout the duration of the study.

Trial Locations

Locations (1)

Polyclinique Jean Villar

🇫🇷

Bruges, France

© Copyright 2025. All Rights Reserved by MedPath